SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue, signaling continued momentum for its SSi Mantra surgical robotic platform. The company, a developer of innovative surgical robotic technologies, achieved $13.9 million in revenue for the quarter, a 39.4% increase from $10.0 million in the same period last year. Gross profit rose 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter (https://nnw.fm/zxrT1).
The robust performance extends to the first half of the year, with revenue reaching $25.0 million, a 65.6% increase from $15.1 million in the first half of 2025. Gross profit for the first half increased 77.5% to $12.4 million, and the gross margin improved, reflecting operational efficiencies and scale benefits.
Underpinning this growth is the expanding adoption of the SSi Mantra system. During the quarter, installations rose 30.4% to 30 systems, bringing the installed base to 224 systems across 12 countries. Cumulatively, 12,272 surgeries have been performed using the platform, a testament to its clinical utility and growing trust among surgeons.
"Our record revenue and continued system installations demonstrate the strong market acceptance of SSi Mantra," said a company spokesperson. "We are also making significant strides in regulatory approvals, which will open new markets and drive further growth."
The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. These regulatory milestones are critical catalysts that could significantly expand the addressable market for SSi Mantra. The U.S. and European markets represent substantial opportunities, and successful clearances would position SS Innovations to compete on a global scale.
Another key differentiator is the company's telesurgery achievements, which extend the clinical profile of SSi Mantra. Telesurgery capabilities allow surgeons to operate remotely, potentially increasing access to specialized surgical care in underserved regions. While system installations remain the primary commercial growth driver, telesurgery showcases the platform's advanced technology and opens possibilities for future service-based revenue streams.
Investors and industry observers view these developments as indicators of the company's long-term potential. The strong revenue growth and expanding installed base provide a solid foundation for future profitability. However, the decline in gross margin in the second quarter warrants attention, as it may reflect increased costs associated with scaling operations or competitive pricing pressures.
SS Innovations continues to focus on innovation and expanding its global footprint. With a growing body of clinical evidence and a clear regulatory roadmap, the company is well-positioned to capitalize on the increasing demand for robotic-assisted surgery. As the healthcare industry shifts toward minimally invasive procedures, SSi Mantra's value proposition becomes increasingly compelling.
For more information about SS Innovations and its latest news, visit the company's newsroom at https://nnw.fm/SSII.
